Protamine-RNA Nanoparticle Stability in Isotonic Solutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protamine-RNA nanoparticles are unstable when diluted in salty pharmaceutical carriers, leading to loss of physical characteristics and biological properties, particularly when formulated for injection in isotonic solutions.
Innovation Solution
Formulating aqueous solutions with a non-electrolyte osmotic agent like glucose to maintain the stability of protamine-RNA particles, keeping electrolyte concentrations below 50 mM, which helps in preserving the size and immunostimulating features of the particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If protamine-RNA nanoparticles are formulated in isotonic salty solutions for injection, then they can be administered parenterally, but they become unstable and lose their physical characteristics and biological properties
Solution Approach 1:
The patent changes the chemical composition parameters of the isotonic solution by replacing traditional electrolyte-based isotonic solutions (like saline) with non-electrolyte-based isotonic solutions containing sugars (glucose, fructose, or mannose) at concentrations of 1-20% w/v. This parameter change maintains isotonicity for parenteral administration while eliminating the destabilizing effect of electrolytes on protamine-RNA nanoparticle stability.
2Ease of manufacture
If protamine-RNA nanoparticles are diluted in salty pharmaceutical carriers, then they can be formulated for injection, but they enlarge over time and lose their size characteristics
Solution Approach 1:
The patent modifies the formulation parameters by using non-electrolyte sugar solutions instead of electrolyte-containing pharmaceutical carriers. This change maintains the ability to formulate injectable products while preserving precise control over particle size (10-990 nm) by preventing electrolyte-induced particle enlargement.
3Adaptability or versatility
If protamine-RNA nanoparticles are formulated with high electrolyte concentrations for isotonicity, then they achieve physiological compatibility, but they lose their immunostimulating features and cytosolic release capability
Solution Approach 1:
The patent changes the isotonicity achievement method from electrolyte-based to non-electrolyte-based solutions. This maintains physiological compatibility (isotonicity) while preserving the biological functions of the nanoparticles, including immunostimulating features and cytosolic RNA release capability, which are lost in electrolyte-containing formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach ensures physical stability and maintains the biological properties of protamine-RNA nanoparticles, allowing for effective immunostimulation and cytosolic RNA delivery even in isotonic conditions.
Implementation Method 1
The particles are formulated in an aqueous solution comprising a non-electrolyte osmotic agent and less than 50 mM electrolytes
Data Source
AI summary
The present invention relates to stable low-salt aqueous formulations of particles comprising a polycation, preferably protamine, and RNA, which formulations are preferably isotonic, to pharmaceutical compositions or kits comprising such formulations and to their use in medicine. It further relates to methods for preparing the formulations of the invention and to methods for physically stabilizing particles comprising a polycation, preferably protamine, and RNA.